Evidence map›Paper›PMID 30917547›Full record

ArticleCancers2019

Store-Operated Calcium Entry Contributes to Cisplatin-Induced Cell Death in Non-Small Cell Lung Carcinoma.

Roberta Gualdani, Marie de Clippele, Ikram Ratbi, Philippe Gailly, Nicolas Tajeddine

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. CaBiophysics reports · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Blockade of store-operated calcium entry sensitizes breast cancer cells to cisplatin therapy via modulating inflammatory response.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  12. Review
  13. Review
  14. Crosstalk between CaInternational journal of molecular sciences · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Mechanism of CaBiology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Roberta GualdaniLaboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, Brussels 1200, Belgium. roberta.gualdani@uclouvain.be.
Marie de ClippeleLaboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, Brussels 1200, Belgium. marie.declippele@uclouvain.be.
Ikram RatbiLaboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, Brussels 1200, Belgium. ikram.ratbi@uclouvain.be.
Philippe GaillyLaboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, Brussels 1200, Belgium. philippe.gailly@uclouvain.be.
Nicolas TajeddineLaboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, Brussels 1200, Belgium. nicolas.tajeddine@uclouvain.be.
UCLouvain · BE

Funding

Fédération Wallonie-Bruxelles ARC17/22-083Fonds De La Recherche Scientifique - FNRS EQP U.N011.17Fonds De La Recherche Scientifique - FNRS J0080.17
6 · The paper itself

Abstract

Cisplatin (CDDP) is one of the principal chemotherapeutic agents used for the first-line treatment of many malignancies, including non-small cell lung carcinoma (NSCLC). Despite its use for over 40 years, its mechanism of action is not yet fully understood. Store-operated calcium entry (SOCE), the main pathway allowing Ca

Indexed as

apoptosiscisplatinmitochondrial calciumnon-small cell lung carcinomareactive oxygen speciesstore-operated calcium entry

Identifiers

PMID30917547
PMCPMC6468672
OpenAlexW2923388010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.